Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1089/nat.2016.0657

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Annemieke Aartsma-Rus
55
,
Arthur M. Krieg
91
Nucleic Acid Therapeutics4.00
Volume: 27, Issue: 1, Pages: 1 - 3
Published: Feb 1, 2017
Abstract
Nucleic Acid TherapeuticsVol. 27, No. 1 Issues in DevelopmentOpen AccessFDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen SagaAnnemieke Aartsma-Rus and Arthur M. KriegAnnemieke Aartsma-RusLeiden University Medical Center, Leiden, the Netherlands.Search for more papers by this author and Arthur M. KriegCheckmate Pharmaceuticals, Cambridge, Massachusetts.Search for more papers by this authorPublished...
Paper Fields
Paper Details
Title
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
DOI
doi.org/10.1089/nat.2016.0657
Published Date
Feb 1, 2017
Journal
Nucleic Acid Therapeutics
Volume
27
Issue
1
Pages
1 - 3
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.